Extended Data Fig. 2: Kaplan–Meier plot of progression-free survival. | Nature Medicine

Extended Data Fig. 2: Kaplan–Meier plot of progression-free survival.

From: Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Extended Data Fig. 2

Median progression-free survival (PFS) for patients who received pembrolizumab only in the adjuvant setting was 72.5 d; patients who received neoadjuvant and adjuvant pembrolizumab had a median PFS of 99.5 d (hazard ratio 0.43, 95% confidence interval 0.20–0.90; two-sided P = 0.03 by log-rank test).

Back to article page